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Extremely high and specific activity of DNA enzymes in cells with 
a Philadelphia chromosome 
Masaki Warashina, Tomoko Kuwabara, Yuka Nakamatsu and Kazunari Taira 
Background: Chronic myelogenous leukemia (CML) results from 
chromosome 22 translocations (the Philadelphia chromosome) that creates 
BCR-ABL fusion genes, which encode two abnormal mRNAs (b3a2 and 
b2a2). Various attempts to design antisense oligonucleotides that specifically 
cleave abnormal L6 BCR-ABL fusion mRNA have not been successful. 
Because b2a2 mRNA cannot be effectively cleaved by hammerhead ribozymes 
near the BCR-ABL junction, it has proved very difficult to engineer specific 
cleavage of this chimeric mRNA. Nonspecific effects associated with using 
antisense molecules make the use of such antisense molecules questionable. 
R~ults: The usefulness of DNA enzymes in specifically suppressing expression 
of L6 BCR-ABL mRNA in mammalian cells is demonstrated. Although the 
efficacy of DNA enzymes with natural linkages decreased 12 hours after 
transfection, partially modified DNA enzymes, with either phosphorothioate or 
2’-O-methyl groups at both their 5’ and 3’ ends, remained active for much longer 
times in mammalian cells. Moreover, the DNA enzyme with only P’-O-methyl 
modifications was also highly specific for abnormal mRNA. 
Conclusions: DNA enzymes with P’-O-methyl modifications are potentially 
useful as gene-inactivating agents in the treatment of diseases such as CML. In 
contrast to conventional antisense DNAs, some of the DNA enzymes used in this 
study were highly specific and cleaved only abnormal BCR-ABL mRNA. 
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Introduction 
The Philadelphia chromosome is a cytogenetic abnormal- 
ity that results from reciprocal chromosomal translocations 
t(9; 22) (q34, qll) and it is characteristic of cells from 
patients with chronic myelogenous leukemia (CML) [l]. 
The translocations can be subdivided into two types: KZX 
and L6 translocations. Both translocations result in the for- 
mation of the BCR-ABL fusion gene, which encodes two 
types of mRNA: b3a2 mRNA (consisting of BCR exon 3 
and ABL exon 2) and b2aZ mRXA (consisting of BCR exon 
2 and ABL exon 2; Figure la) [Z-7]. Both these mRNAs are 
translated into a protein of 210 kDa (pZ10”‘.‘KY4HL), which is 
unique to malignant CbIL cells [8]. 
In designing ribozymes and antisense DNA that can disrupt 
expression of a chimeric RXA specifically, it is necessary 
to target the junction sequence. Otherwise, expression of 
normal mRNAs that share part of the sequence of the 
chimeric RIiA will also be affected, with resulting damage 
to host cells. In the case of b3aZ mRNA, a site potentially 
susceptible to cleavage by the hammerhead ribozyme is 
located three nucleotides upstream from the junction 
(Figure lb). A conventional hammerhead ribozyme might 
therefore be expected to cleave specifically the abnormal 
b3a2 mRNA generated from K28 translocations. Indeed, 
several examples of such cleavage have been reported 
[9-161. In contrast, in the case of b2a2 mRNA. which 
results from I,6 translocations, as well as in the case of 
some K28 translocations (Figure la), there are no hammer- 
head ribozyme target sequences within two or three nucleo- 
tides of the BCR-ABL junction. When the cleavage site is 
located further from the junction, nonspecific cleavage of 
normal mRNAs by hammerhead ribozymes cannot be 
avoided (Figure 1 b). Previous attempts at engineering spe- 
cific cleavage by the hammerhead ribozyme have involved 
a combination of a long antisense arm, which recognizes 
the junction, and a ribozyme sequence [17,18]. Hammer- 
head ribozymes can cleave RNAs even if one of the binding 
arms is only two or three nucleotides long [19,.20]. We note 
that ribozymes other than the hammerhead, such as the 
hairpin, might cleave the BCR-ABL junction of b2aZ mRNA 
specifically and might, therefore, be worth investigating 
further. In the case of antisense DNAs, oligonucleotides of 
a certain length are necessary for stable binding of the anti- 
sense molecule to its target, resulting in decreases in speci- 
ficity [Zl-271. The utility of such antisense-type ribozymes 
(and antisense D&As) remains questionable because of 
their low specificity [21-291. 
In a recent study, Santoro and Joyce [30] successfully 
selected DNA enzymes that were able to cleave RNA 
molecules with any sequence by use of a selection proce- 
dure in a&. These DNA enzymes are rather similar to 
conventional hammerhead ribozymes because they consist 
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Figure 1 
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chromosomal translocations (K28 and L6) that are associated with 
BCR-ABL translocations and fusion mRNAs. (a) The two types of 
chronic myelogenous leukemia (CML) and the corresponding fusion 
mRNAs are depicted. Red boxes represent BCR exons and green 
boxes represent ABL exon 2. Dotted lines connecting BCR and ABL 
exons indicate alternative splicing pathways. (b) Possible sites of 
L6 b2a2 mRNA, which mainly results from L6 translocations (and some 
cleavage by ribozymes and DNA enzymes are indicated by scissors. In 
K28 translocations), there are no triplet sequences near the BCR-ABL 
junction that are potentially susceptible to cleavage by hammerhead 
ribozymes. In contrast, DNA enzymes can cleave L6 b2a2 mRNA 
because of their high flexibility in the choice of cleavage site. 
of a 15 deoxyribonucleotide catalytic domain and, in addi- 
tion, metal ions, such as Mg2+, are necessary for catalytic 
activity ([31,32]: Zhou and K.T., unpublished observa- 
tions), as is the case for hammerhead ribozymes, which 
are recognized as metalloenzymes [33-44]. The catalytic 
domain is flanked by two substrate-recognition domains of 
seven or eight deoxyribonucleotides each. and the RNA 
substrate is bound through Watson-Crick base pairing 
(Figure 2a). These DNA enzymes can be divided into two 
types. Type I DNA enzymes can cleave an RNA sequence 
at a phosphodiester bond that is located between an 
adenine and a guanine residue. The catalytic domain con- 
sists of a four-nucleotide loop adjacent to the cleavage site 
and a stem-loop region that resembles the stem-loop 
region II of the hammerhead ribozyme. The stem-loop 
region in the DNA enzyme is essential for catalysis, 
however [30]. Type II DNA enzymes cleave an RNA 
sequence at a phosphodiester bond between a purine and 
pyrimidine residue. In this case, the catalytic domain con- 
sists of 15 nucleotides (Figure 2). Such DNA enzymes can 
be expected to cleave almost any target Rh‘A substrate 
specifically. With respect to substrate specificity, these 
DNA enzymes might have other advantages, when com- 
pared with hammerhead ribozymes. In general, DXA- 
RNA duplexes are less stable than the corresponding 
RNA-RNA duplexes. In the case of a DNA enzyme, 
therefore, mismatches in binding arms that might be gen- 
erated during binding with a nontarget mRNA, such as 
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Figure 2 
DNA enzymes used in this study. 
(a) Nucleotide sequences of DNA enzymes 
targeted to the L6 BCR-ABL (b2a2) mRNA 
substrate. Red and blue letters indicate 
phosphorothioate linkages and 
2’-C-Me-substituted residues, respectively. 
(b) Stabilities of DNA enzymes in human 
serum. Fully 32P-labeled DNA enzyme 
(20 kcpm) was incubated in 90% human serum 
at 37°C for the indicated period. Degraded 
products were separated by electrophoresis on 
a 20% polyacrylamide/7 M urea denaturing gel 
and were detected by a Blo-Image Analyzer 
(BAS2000; Fuji Film, Tokyo). 
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normal ABL mRNA, would inhibit cleavage activity to a 
greater extent than in the case of a ribozyme. 
We are interested in the specific cleavage of b2a2 mRNA. 
There are several sites of potential cleavage by the DIVA 
enzymes within three nucleotides of the BCR-ABL junc- 
tion in this mRNA. We demonstrated previously that the 
DNA enzymes specifically cleave BCR-ABL chimeric LO 
(bZa2) mRh‘A in aitro [28]. We found that our DNA 
enzyme, designated Dz3 (which originated from a type II 
DNA4 enzyme). was the most efficient of all those that we 
tested [28]. The usefulness of Dz3 in GV remained to 
be examined, however. In this study. we investigated the 
activity and specificity of Dz3 in cultured cells. To cleave a 
chimeric mRNA such as BCR-ABL mRNA. specific recog- 
nition of abnormal mRI%A and the absence of any effect on 
normal mRNA are essential. Accordingly, we also investi- 
gated the effects of introducing modified oligonucleotides 
into Dz3 on specificity and cleavage activity in mammalian 
cells using reporter constructs that included a luciferase 
gene. In addition, we monitored cleavage of an endoge- 
now target in leukemic BVI 73 cells. 
Results and discussion 
Design of DNA enzymes and stability of DNA enzymes in 
human serum 
The design of the DNA enzymes and the choice of the 
target site for the specific cleavage of L6 BCR-iLBL (b2aZ) 
mRNA were based on results published previously [28]. 
In a previous study we found that the most effecti\-e DNA 
enzyme in &-a was Dz3, 31 nucleotides (nt) in length, 
that cleaves between guanine and cytosine residues on 
the 3’side of the junction of BCR exon 2 and ABL exon 2 
in L6 BCR-ABL mRNA. Moreover, Dz3 did nor cleave 
normal ABL mRNA in vitro. To test the possibility of using 
such a DK14 enzyme in mammalian cells, we examined 
several variants of Dz3. Dr.3 has a catalytic domain of 15 nt 
in length that is flanked by two 8-nt substrate-binding 
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Figure 3 
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Cleavage activities and specificities of DNA enzymes in vitro. 
(a) Relative extents of DNA-enzyme-mediated cleavage of the 
BCR-ABL substrate mRNA (121-mer). (b) Specificity of DNA-enzyme- 
mediated cleavage of ABL substrate mRNA (92-mer). Each DNA 
enzyme (1 PM) and 5’-32P-labeled substrate (2 nM) were incubated at 
37% for the indicated times in a solution that contained 50 mM 
Tris-HCI (pH 8.0) and 25 mM MgCI,. Each reaction mixture was then 
subjected to electrophoresis on a 5% polyacrylamideI7 M urea gel. 
arms. In general, for efficient catalysis Z+Z v&o, the length 
of the antisense arms that recognize the target sequence 
and the introduction of modified oligonucleotides to 
enhance resistance to nucleases in viva are both important. 
We therefore prepared longer-armed Dz3 (LDz3) and 
several modified Dz3 forms, as shown in Figure 2a. LDz3 
has binding arms of 15 nt each. SDz3 and SLDz3 corre- 
sponded to Dz3 and LDz3 but have two phosphorothioate 
substitutions at both their 5’ and 3’ ends (for a total of four 
modifications). MeODz3 corresponds to Dz3 but has two 
2’-O-methyl-substituted residues at both the 5’ and the 3’ 
ends (for a total of four modifications). 
To confirm the nuclease resistance of the modified DNA 
enzymes, we analyzed the stability of Dz3, SD23 and 
MeODz3 in human serum. Fully 3ZP-labeled oligonucleo- 
tides were incubated in 90% human serum (collected as 
described in [45]) for 5, 20 and 60 min at 37°C and the 
products were analyzed by electrophoresis on a 20% poly- 
acrylamide/7 M urea denaturing gel. As can be seen in 
Figure 2b, significant portions of the Dz3 were degraded 
after 60 min. In contrast, the modified SDz3 and MeODz3 
remained intact, even after a 60 min incubation. It is clear, 
therefore, that introducing two phosphorothioate linkages 
or two 2’-O-methyl-substituted residues at both the 5’ 
and 3’ ends (for a total of four modifications) significantly 
enhanced resistance to nucleases. 
Cleavage activities and specificities of DNA enzymes for 
the chimeric BCR-ABL L6 (b2a2) mRNA substrate 
Before examining the DNA enzymes in mammalian cells 
we investigated the effects of the modifications described 
above on cleavage activity and specificity against the 
chimeric BCR-ABL (b2a2) substrate and the normal ABL 
substrate (which are 121 and 92 nt long, respectively). 
The relative cleavage activities and the specificities of 
each DNA enzyme for the chimeric BCR-ABL substrate 
(121-mer) and the normal ABL substrate (92-mer) are 
shown in Figure 3. Reactions were performed in 50 mM 
Tris-HCl (pH 8.0) and 25 mM MgCl, under enzyme-satu- 
rating (single-turnover) conditions at 37°C. Each of the 
DNA enzymes cleaved the BCR-ABL substrate at the 
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Table 1 
Kinetic parameters of cleavage of the BCR-ABL substrate 
mRNA (Ill-mer). 
DNA enzyme k,, (x 1 Om2 min-I) K, (PM) k-,/K, (PM-’ min-l) 
Dz3 0.82 0.11 0.075 
LDz3 1.3 0.012 1.1 
SD23 0.52 0.10 0.052 
SLDz3 1.7 0.010 1.7 
MeODz3 1 .o 0.10 0.10 
Rate constants were measured in 50 mM Tris-HCI (pH 8.0) and 25 mM 
MgCI, under enzyme-saturating (single-turnover) conditions at 37°C. 
Rate constants are averages of results from two sets of experiments. 
anticipated site, and neither the thio substitutions nor the 
2’-Me0 residues significantly inhibited the cleavage activ- 
ity (Dz3, lanes 2-4; SDz3, lanes 8-10; hleODz3, lanes 
14-16; Figure 3a). These results were not surprising 
because the introduced modifications were sufficiently far 
from the catalytic domain, as had also been the case for 
modified synthetic hammerhead ribozymes [45--49]. 
Highly specific DNA enzymes should cleave only the 
chimeric BCR-ABL substrate. In contrast, DNA enzymes 
with reduced specificity would be expected to cleave not 
only the chimeric BCR-ABL substrate but also the normal 
ABL mRXA because one of the two recognition arms of 
our various DNA enzymes can hybridize with part of the 
normal ABL mRNA. As can be seen from Figure 3b, the 
modifications by themselves did not affect the specificity 
of the DNA enzymes and no products of cleavage of the 
normal mRXA were detected (Dz3, lanes 2-4; SDz3, 
lanes 8-10; MeODz3, lanes 14-16). In contrast, however, 
DNA enzymes that have longer binding arms (LDz3 and 
SLDz3) did cleave the normal ,4BL mRNA to a limited 
extent; this result indicates that these DNA enzymes with 
their relatively long antisense arms recognized not only 
the abnormal BCR-ABL mRNA but also the normal ABL 
mRNA as substrate. Nonspecific cleavage of normal ABL 
mRI%A occurred when we used longer-armed DNA 
enzymes in &PO. This is because, in order to amplify the 
detection of the nonspecific cleavage, we used high con- 
centrations of Mga+ (25 mlC1 MgClJ in the in vitro experi- 
ment. We should mention that the same longer-armed 
DNA enzymes acted with high specificity within mam- 
malian cells, as discussed belovv. 
In order to characterize in further detail the properties of 
the modified DNA enzymes and the longer-armed D&A 
enzymes, we determined kinetic parameters for the cleav- 
age of the BCR-ABL 121-mer mRNA substrate under 
single-turnover conditions. The kinetic parameters (k,,, 
and K,,) are summarized in Table 1. Comparisons of 
kinetic parameters revealed the absence of any significant 
differences in k,,, and K,, values between the modified 
and the unmodified DNA enzymes (Table 1). In the case 
of the longer-armed DNA enzymes, which have approxi- 
mately twice as many nucleotides in their binding arms as 
the parental DNA enzymes, we found that the longer the 
binding arms, the higher the k,,, values and the lower the 
K, values (i.e. overall higher ficar/K4r values; Table 1). In 
terms of k,,,lK,, Dz3 was shown previously to be more 
powerful when a short synthetic oligonucleotide substrate 
of 21 nt was used [%I. It is generally accepted that long 
mRNAs, because of their higher-ordered structures, are 
cleaved less efficiently by ribozymes than corresponding 
short synthetic oligoribonucleotide substrates [SO-521. This 
was also the case for cleavage by DNA enzymes (data 
not shown). 
Comparison of the intracellular activities and specificities 
of the unmodified and modified DNA enzymes using a 
reporter construct in cultured cells 
Having confirmed the specificities and activities of our 
series of DNA enzyme in h-o, we next examined their 
effects in cultured cells using a reporter construct. In order 
to distinguish between the chemical-cleavage activities of 
our DN.4 enzymes and their antisense effects, we pre- 
pared both inactive DNA enzymes and antisense oligonu- 
cleotides as controls. As shown in Figure 4a, antisense 
DNA (D-antisense), which consisted entirely of deoxyri- 
bonucleotides, had a sequence complementary to the target 
sequence of Dz3. The modified antisense molecule, S-anti- 
sense, had two phosphorothioate substitutions at its 5’ and 
3’ ends, as did SDz3. To identify an inactive DXA enzyme, 
we synthesized three variants of Dz3 (G,,-+A, GZZ-+A and 
A2,-+G in Figure 4b) and examined their cleavage accivi- 
ties in 2:&o. G,,A has an A residue instead of G,4 in the 
parental Dz3. G,,A and A,,G have A and G residues 
instead of the GLZ and A,, residues in the parental Dz3, 
respectively. Cleavage of the BCR-ABL substrate (121-mer) 
by these DI%A enzyme variants is shown in Figure 4b. 
Because G,,.4 had no cleavage activity, even when incu- 
bated with the substrate for 6 h, we used it as an inactive 
DIVA enzyme in subsequent studies, renaming it IDz3 
(Figure Ib). \Ve also prepared thio-substituted IDz3, which 
we named SIDz3. 
To evaluate the intracellular activities of the various 
oligonucleotides (Dz3, LDz3, IDz3, SDz3, SLDz3, SIDz3. 
MeODz3, D-antisense and S-antisense), we co-transfected 
HeLa cells with the oligonucleotides, together with a 
target-gene-expressing plasmid that encoded a chimeric 
target BCR-ABL (or ABL) sequence and a gene for 
luciferase, pBZA2-luc (or pABL-ILK) in combination with 
Lipofectin (Figure 5). The junction-expressing plasmid 
pB2.42~luc contained a 300-nt sequence that encompassed 
the BCR-ABL junction of L6 bZa2 mRN.4. The plasmid 
pilBL--luc contained a 300-nt sequence that encompassed 
the junction between exon 1 and exon 2 of normal i4BL 
mRN,4. ,lfter co-transfection with the oligonucleotides 
242 Chemistry & Biology 1999, Vol 6 No 4 
Figure 4 
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Nucleotide sequences of antisense oligonucleotides and an inactive 
DNA enzyme. (a) Antisense DNA (D-antisense) targeted to the b2a2 
junction of BCR-ABL mRNA and its thio-modified derivative 
(S-antisense; thio-substituted residues are red). (b) Selection of an 
Inactive DNA enzyme (IDz3). Three types of variant DNA enzymes 
with base substitutions at the indicated sites were examined with 
respect to cleavage of the BCR-ABL substrate (121 -mer). G,,-+A 
is inactive and was renamed IDz3. The thio-substituted residues of 
SIDz3 are indicated. 
and transient expression of target genes for 12 h, we 
estimated the intracellular activity of each oligonucleo- 
tide by measuring the luciferase activity in individual 
cell lysates. 
The inhibitory effects were tested at two different oligonu- To use such DNA enzymes in &CO, protection from intra- 
cleotide concentrations and the results of one set of the cellular nucleases is obviously essential. Various kinds of 
experiments are summarized in Figure 6. The luciferase nuclease-resistant oligonucleotide have therefore been 
activity recorded when we used each target-gene-espress- developed [Zl-27,4539,53,.54]. The most popular moditi- 
ing plasmid (pBZAZ-luc or pABL-luc) by itself was taken as cation remains the introduction of phosphorothioate link- 
100%. When 0.3 @I oligonucleotide was used (Figure h), to ages. Previous attempts at using antisense oligonucleo- 
our surprise, the unmodified parental Dz3 suppressed the tides with thio-substituted residues to treat C&IL suggested 
expression of the BCR-ML-luciferase gene in mammalian that the nonsequence-specific inhibition was due to a 
cells both specifically and with extremely high efficacy 
(-99% inhibition). Moreover, it had no inhibitory effect on 
the expression of the normal ABL-luciferase gene (no side 
effects), as expected from our analysis in r&o. LDz3, which 
had slight nonspecific cleavage activity against the normal 
ABL substrate i~z GWU, exhibited not only high effcaq but 
also high specificity in suppression of the BCR-ABL- 
luciferase gene in cultured cells. Although both enzymes 
were very active, LDz3 seemed to be slightly more active 
than Dz3. 
In contrast to Dz3, D-antiscnse inhibited the expression 
of both the BCR-,I1BL-luciferase gene and the 4BL- 
luciferase gene. \lany attempts at using antisense oligonu- 
cleotides to suppress specifically the expression of BCR- 
ABL fusion mRIKA have been reported [21-271. Despite 
the initial optimism. recent studies have failed to demon- 
strate that any appropriate antisense oligonucleotide can 
specificall>- suppress the expression of RCR-24BZ, fusion 
mRNA. It has also been suggested that nonspecific inhi- 
bition by such antisense oligonucleotides is the result of 
nonantisense effects [21-271. In agreement with such 
recent reports, our antisense DNhs failed to suppress 
specifically the reporter constructs in HeLa cells. DNA 
enzymes include antisense sequences that allow them to 
recognize their target mRNA, but these sequences are 
interrupted by the catalytic loop and, as a result, lower 
affinity and higher specificity for the substrate are 
expected. Indeed, as shown in Figure 6, the inactive DNA 
enzyme IDz3 did not have any inhibitory effect on the 
expression of the BC’R-LlBL-luciferase gene or the ABl..- 
luciferase gene. This result also demonstrates that the 
inhibitory effects of the DNA enzymes did not originate 
from antisensc effects but from the specific chemical- 
cleavage activity of the DKA enzymes themselves. hfore- 
over, although the inactive DNA enzymes could potentially 
promote RNase-H-mediated cleavage of the substrate as 
observed in experiments NI cifm (Figure 7; the level of 
RNase H was adjusted such that both DNA-enzyme- and 
RNase-H-mediated cleavage products were discernible 
on the gel), the results shoun in Figure 6 clearly demon- 
strate that the inhibitory effects of DNA enzymes did 
not originate from the RIKase H activity in cells. Appar- 
ently. the specific chemical-cleavage activity of the DNA 
enzymes was significantly higher than the RNase-H-medi- 
ated cleavage activity in eizw, at least under the conditions 
of our investigations. 
Research Paper Cleavage of BCR-ABL mRNA by DNA enzymes Warashina et al. 243 
Figure 5 
In viva assay system. (a) Schematic 
representation of the assay for determining 
DNA enzyme activity in HeLa cells. 
(b) Photomicrographs of HeLa cells and 
BVl 73 leukemic hematopoietic cells 
transfected with the fluorescently labeled DNA 
enzyme. Cells were transfected with 
fluorescein end-labeled DNA enzyme (Dz3) at 
0.3 pM concentrations as described in the 
Materials and methods section. Samples were 
examined using a fluorescent microscope 12 
hours after transfection (Nikon, Tokyo). 
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nonantisense mechanism [Zl-271. In order to investigate 
the effects of thio substitutions, we designed four types 
of partially thio-substituted oligonucleotides, namely, 
SDz3, SLDz3, SIDz3 and S-antisense, as described above, 
and we examined their activities in mammalian cells 
(Figure 6). In most previous studies, almost all the link- 
ages of antisense oligonucleotides have been thio substi- 
tuted. In the present study, however, we introduced only 
four thio substitutions into each oligonucleotide, hoping 
to minimize nonsequence-specific effects. Nevertheless, 
SDz3, SLDz3, SIDz3 and S-Antisense all had strong 
inhibitory effects not only on the expression of the BCR- 
ilBL-luciferase gene but also on the expression of the 
AB,!,-luciferase gene in HeLa cells. In particular, despite 
the fact that Dz3 and LDz3 specifically inhibited the 
expression of the BCR-ABL-luciferase gene, no similar 
specificity was observed when the respective thio-sub- 
stituted counterparts were tested. Our assay system, as 
shown schematically in Figure 5a, is clearly useful for 
estimating the efficacy and specificity of functional 
oligonucleotides in mammalian cells. hloreover, our 
present results highlight the danger of introducing thio 
linkages even in limited numbers. 
The inhibitory effects of the thio-substituted oligonu- 
cleotides were also tested at higher concentrations (10 @/I, 
data not shown). In this assay, in contrast to the experi- 
ments summarized in Figure 6 (in which the oligonu- 
cleotides and the target-gene-expressing plasmid were 
simultaneously added to cells), because of the higher 
concentrations of oligonucleotides used, the target-gene- 
expressing plasmids were introduced first to cells with 
Lipofcctin and then, 2 h after incubation, the oligo- 
nucleotides were introduced to the cells again using 
Lipofectin. As a result, when the oligonucleotides were 
introduced, the cells had already produced some luciferase, 
reflecting the higher background level of luciferase activ- 
ity. Here again, in agreement with the results shown in 
Figure 6, the DKA enzymes. with the exception of the 
thio-substituted enzymes, suppressed the expression of 
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Intracellular activities and specificities of DNA enzymes in HeLa cells. 
The effects of DNA enzymes on the chimeric BCR-ABL-luciferase 
gene and the ABL-luciferase gene (red and green, respectively) were 
detected with 0.3 uM DNA enzyme. HeLa cells were co-transfected 
with each oligonucleotide together with the target gene-expressing 
plasmid in combination with Lipofectin. Luciferase activity was 
normalized by reference to the efficiency of transfection, which was 
determined by monitoring the activity of the product of a co-transfected 
gene for f5galactosidas.e (see the Materials and methods section). 
These data are averages of results from two sets of experiments. 
the BCR-AM-luciferase gene in mammalian cells both 
specifically and with high efficacy (data not shown). 
In contrast to the thio-substituted DNA enzymes, the 
DNA enzyme with two 2’- methoxy-substituted residues 
at each end (MeODz3) specifically and effectivrely sup- 
pressed expression of the BCR-ABL-luciferase gene in 
cultured cells. This result suggests that such a Di%A 
enzyme could potentially be used in CZ’UO and also suggests 
that 2’ methoxy groups are suitable for modifying such 
enzymes. Introducing phosphorothioate linkages, which 
resulted in nonspecific damage not only to the abnormal 
gene but also to the normal gene, seems to be less suit- 
able. In designing oligonucleotides with the potential to 
disrupt chimeric RNAs, it is necessary to avoid nonspecific 
effects by the introduced modifications on normal genes. 
Efficacies and specificities of the unmodified and modified 
DNA enzymes against an endogenous BCR-ABL cellular 
target in BV173 cells 
Because our DNA enzymes acted with high efficacy and 
specificity against a reporter-gene construct in HeLa cells, 
we decided to examine the activity of the DNA enzymes 
against an endogenous BCR-ABL (L6 bZa2 mRNA) cel- 
lular target. Because BV173 cells, which were originally 
derived from a CML patient, are Philadelphia chromo- 
some-positive, they express the endogenous gene target 
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RNase H-mediated cleavage of the RNA substrate (S31). After 
hybridization of S31 with the respective DNA enzyme or antrsense 
DNA, reactions with RNase H were initiated under conditions where 
both DNA-enzyme- and RNase-H-mediated cleavage could occur. The 
substrate and products were separated by electrophoresis on a 20% 
polyacrylamidel7 M urea denaturing gel and were detected by 
autoradiography. C, labeled 531 (control); P, labeled S31 treated with 
Dz3 in the absence of RNase H. Red arrows indicate the cleavage 
products mediated by DNA enzymes. 
[Zl-27,.55]. In BV173 cells, disrupting expression of the 
BCR-ABL gene induces apoptosis [21-271. We compared 
the efficacies of Dz3. SDz3 and XleODz3, as representa- 
tive DNA enzymes, together with the inactive control 
(IDz3), by examining the viability of BV173 cells that had 
been transfected with each DNA enzyme. In addition to 
BV173 cells, we used HY cells, which are derived from 
human T cells, and express normal ABL mRNA, as a 
control. We confirmed, using a fluorescently labeled oligo- 
nucleotide (Dz3 with 6-carboxyfluorescein at its 5’ end) 
and Lipofectin, that all these cells could be transfected 
with oligonucleotides (Figure 5b). 
We first examined MeODz3 as the best representative 
example of our DNA enzymes. We expected that it would 
exhibit high efficacy and specificity: in addition to nuclease 
resistance, we examined its effects on H9 and BV173 cell 
morphology. Upon introduction of MeODz3, an examina- 
tion of BV173 cells by light microscopy, after staining with 
the DK.A-binding fluorochrome Hoechst 33342, revealed 
typical apoptotic morphology, which included condensed 
chromatin, fragmented nuclei and shrunken cell profiles 
(Figure 8a, bottom right). It was clear that MeODz3 caused 
apoptotic cell death specifically in BV173 cells and had no 
similar effect on normal H9 cells (Figure Xa, top right). As 
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Figure 8 
Efficiency of DNA-enzyme-mediated cleavage 
of an endogenous BCR-ABL mRNA target. 
(a) Morphology of H9 and BVl73 cells 
treated separately with IDz3, SD23 or 
MeODz3. After 12 h from transfection of each 
DNA enzyme, cells were stained with 
10 pg/ml Hoechst 33342 (DNA-binding 
fluorochrome) for 15 min for studies of nuclear 
morphology. After washing and mounting in 
90% glycerol120 mM Tris (pH 8.0)/0.1% 
N-propyl gallate, slides were examined under 
a fluorescent microscope (Nikon, Tokyo). Not 
only BV173 cells introduced with SD23 and 
MeODz3, but also H9 cells introduced with 
SD23 exhibited typical apoptotic morphology. 
(b) Viability of BV173 and H9 cells treated 
with DNA enzymes. Cell viability was 
determined using the trypan blue exclusion 
test. These data are averages of results from 
two sets of experiments. 
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expected, SDz3 caused apoptotic cell death not only in 
BV173 cells but also in H9 cells. Because IDz3 did not 
change the morphology of either cells line, the apoptotic 
cell death caused by hleODz3 must have originated from 
its cleavage activity in BV173 cells. 
In order to analyze quantitatively the efficacies and speci- 
ficities of three of our DNA enzymes, Dz3, SDz3 and 
hIeODz3, in BV173 and H9 cells, we examined the 
ability of cells to exclude trypan blue dye after transfec- 
cion with each DNA enzyme in combination with Lipo- 
fectin. As can be seen in Figure Xb, for the first 8 h, each 
DNA enzyme exhibited high but dissimilar activity in 
BV173 cells. Unmodified, nuclease-sensitive Dz3 started 
to lose activity about 10 h after transfection, and neither 
Dz3 nor MeODz3 caused the death of any H9 cells, 
which expressed normal ABL mRNA (Figure Xb). demon- 
strating the expected high specificity for targeting the 
chimeric BCR-ML gene (i.e. the absence of side effects 
in normal cells). In contrast, SDz3 induced the death of 
both BV173 and H9 cells, consistent with the result that 
thio-substituted oligonucleotides inhibited the expres- 
sion of both BCR-ABL and normal ABL genes in the 
reporter constructs (Figure 6). In most studies, antisense 
oligonucleotides are added several times periodically to 
cells; we added each DNA enzyme to cells only once in 
the present study. The decrease in the relative number of 
apoptotic cells 8 h after addition of Dz3 and 36 h after the 
addition of SDz3 is most probably due to degradation of 
the DNA enzymes by nucleases. hleODz3 had the longest- 
lasting continuous activity against the endogenous target 
gene, a result that underlines, yet again, the appropriate 
nature of the 2’ methoxy modification. 
Evidence against the cleavage of RNAs during their 
isolation procedures in vitro 
Because the DNA4 enzymes were expected to overcome 
the BCR-/lBL-mediated inhibition of apoptosis by cleaving 
BCR-ABL mRKA. we tried to detect the anticipated 
cleavage products directly using h‘orthern blotting analysis 
(Figure 9). It is possible that the target mRNAs were 
cleaved by the DX4 enzymes during the RiXA extraction 
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Direct detection of the products of cleavage, within BV173 cells, of 
L6 BCR-ABL mRNA by Northern blotting analysis. As long as a 
monophasic solution of phenol is used for the extraction of total 
RNAs [29,56-581, no cleavage occurs during RNA isolation. See 
text for details. 
process. In order to exclude this possibility, a parallel, 
control experiment was set up. Total RNA from BV173 
cells that did not contain DNA enzyme was extracted with 
the extraction buffer (a monophasic solution of phenol; 
see the Materials and methods section) that contained the 
active DNA enzyme MeODz3. I_Jsing Northern blotting 
analysis, we were only able to detect intact BCR-ABL 
mRlNA: no cleavage products were detected (data not 
shown). This finding is in agreement with our previous 
result with ribozymes [29]. In a control experiment, cells 
(BaF3/p210BCR7H-qRk cells) expressing only the target RX4 
(substrate) were mixed, just before the RNA-isolation pro- 
cedure, with cells (transformed BaF3 cells) that expressed 
only the ribozyme, and the total RNA was isolated from the 
mixture [29]. Northern blotting didn’t detect any cleavage 
products, a clear demonstration that the cleavage had 
occurred within the cells but not during the R&A isolation 
procedure in GPO. These results led us to the conclusion 
that the apoptosis observed was a result of cleavage of 
BCR-ABL mRNA by the ribozyme, with resultant deple- 
tion of p210RCR-ABL protein in the hematopoietic cells (the 
p210BCR-1H’, protein is a cytoplasmic, membrane-associated 
protein that has a constitutively high level of tyrosine kinase 
activity that prolongs the survival of hematopoietic cells by 
inhibiting apoptosis). 
The above-mentioned two sets of control experiments 
clearly demonstrate that, as long as a monophasic solution 
of phenol is used for RN.4 extraction [29,56-583, the 
cleavage products we detect using Northern blotting 
analysis do not originate from cleavage during the RNA 
isolation procedure but from cleavage within the cells. 
Direct evidence for cleavage of L6 BCR-ABL mRNA by the 
DNA enzymes 
Total RNA from DNA enzyme-treated BV173 cells were 
extracted 0, 4, 8, 12 and 36 h after the addition of each 
DNA enzyme. The lengths of the L6 BCRABL target 
mRNA (about X.5 kilobases; top band Figure 9) and the 
cleavage product (about 5.3 kilobases; bottom band) were 
exactly as anticipated. The two middle bands are nonspe- 
cific and thus could be washed off by more extensive and 
rigorous washing at a higher temperature when a longer 
probe was used (data not shown; a shorter probe was 
used in Figure 9). Because the bands were sharper in the 
Northern blotting data shown in Figure 9 than those 
obtained with the longer probe, we display those ICorthern 
blotting data with nonspecific bands in Figure 9. No 
reduction in the level of expressed L6 BCR-ABL mRNA 
and no cleaved product was detected in the presence of 
the inactive DNA enzyme IDz3 (Figure 9a). In contrast, 
in all cases of treatment with active DNA enzymes, we 
detected cleaved fragments (Figure 9b-d). Although the 
Dz3-cleavage product was detected in total RNA extracted 
4 and 8 h after the addition of Dz3, the cleaved product 
disappeared and the amount of intact L6 BCR-ABL 
mRN,4 returned to the basal level after prolonged incu- 
bation (consistent with the results in Figure 8b). In the 
case of SDz3, the cleaved product was also detected, 
indicating that SDz3 retained cleavage activity in cells in 
spite of the nonsequence-specific effects due to phos- 
phorothioate linkages. Most importantly, it was clear that 
the amount of cleaved product was larger and the product 
was continuously detectable for a longer time in cells 
treated with MeODz3 (Figure 9d) than in cells treated 
with Dz3 or SDz3. 
Detection of the cleaved fragment proved that the DNA 
enzymes were catalytically active in cultured cells. hlore- 
over, we confirmed that the apoptosis of cells, as shown in 
Figure 8, with the exception of cells treated with SDz3, 
originated from the cleavage of BCR-ABL mRNA by a 
DN,4 enzyme, with resultant depletion of the ~210~~~+‘~‘. 
protein in BV173 cells [29]. 
Significance 
Chronic myelogenous leukemia (CML) cells are cytoge- 
netically characterized by the Philadelphia chromosome, 
which results from translocations on chromosome 22. 
The translocations create BCR-ABL fusion genes, which 
encode two abnormal mRNAs (b3a2 and b2a2). Because 
both the abnormal p2108cR-ABL chimeric protein and 
the wild-type ~145 c-ABL protein are negative regula- 
tors of apoptosis t59-661, antisense molecules with low 
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specificity can induce apoptosis in CML cells by inhibit- 
ing expression of normal ABL mRNA (~145 c-ABL) 
in addition to blocking the BCR-ABL (p210BCR-ABL) 
pathway. Previously designed antisense oligonucleotides 
that targeted the b3a2 or b2a2 mRNA had inhibitory 
effects on the proliferation of leukemic cells that 
expressed both b3a2 and b2a2 mRNAs, which clearly 
demonstrates the nonspecificity of these oligonucleotides. 
Moreover, inhibition by a nonantisense mechanism was 
also recognized 121-271. 
In this study, we demonstrated that b2a2 BCR-ABL 
mRNA expression can be specifically inhibited by DNA 
enzymes. We examined expression of both reporter-gene 
constructs and an endogenous cellular target. The DNA 
enzymes exhibited high efficacy, and we confirmed, 
using Northern blotting analysis, that the DNA enzymes 
had cleavage activity in cultured cells and, moreover, 
that the apoptosis caused by the DNA enzymes in 
leukemic cells originated from the cleavage of the target 
BCR-ABL mRNA. Among the limited modifications 
that we introduced, 2’-OMe-substitution appeared to be 
the most effective, because introduction of two such modi- 
fications at each end of our DNA enzyme (MeODz3) 
resulted in significant resistance to nucleases without 
any loss of specificity. In contrast, using a thio-substi- 
toted version of the same DNA enzyme (SDz3) resulted 
in complete loss of specificity despite an increase in 
nuclease resistance. 
In developing nucleic-acid drugs for treating CML, in 
particular in the case of the L6 translocations on which 
we focused our attention in this study, conventional 
ribozymes (with exception of a new motif described in 
[29,56,67]) might not be the best choice because of the 
lack of a suitable cleavage site in the target mRNA 
[28]. Similarly, because of a lack of substrate specificity 
against the chime& target, antisense oligonucleotides 
might also not be appropriate. In contrast, the DNA 
enzymes used here exhibit high specificity for the chimeric 
target. Because DNA enzymes are easier to synthesize, 
easier to handle and more stable in z&o than ribozymes, 
appropriately modified DNA enzymes might turn out to 
be powerful catalytic nucleic-acid drugs. 
Materials and methods 
Synthesis of antisense DNAs and DNA enzymes 
DNA enzymes and antisense DNAs were synthesized chemically on a 
DNA synthesizer (model 394; PE Applied Biosystems, Foster City, 
CA). Reagents for DNA synthesis were purchased from Glen Research 
(Sterling, VA). Oligonucleotides were purified as described in the user 
bulletin from ABI (no. 53; 1989) with minor modifications. In brief, syn- 
thesized oligonucleotides were incubated in 2 ml of ammonia solution 
at 55°C for 8 h to remove protecting groups. The crude deprotected 
oligonucleotides were purified on a OPC (oligonucleotide purification 
cartridge) column and then by electrophoresis on a 20% polyacry- 
Iamide/ M urea denaturing gel with subsequent extraction from the gel 
with elusion buffer (0.3 M ammonium acetate, 0.1 mM EDTA, 20 mM 
Tris-HCI, pH 8.0) as described previously [68]. The sequences of 
oligonucleotides are indicated in Figures 2 and 4. Modified oligonu- 
cleotides were obtained from Oligo Service (Tsukuba, Japan). In addi- 
tion, fluorescently labeled Dz3, which had 6carboxyfluorescein at the 
5’ end, was synthesized as described previously [69,70]. Further purifi- 
cation of these oligonucleotides was based on poiyacrylamide gel elec- 
trophoresis, as described above [68]. 
Preparation of target substrates, namely, ABL and BCR-ABL 
mRNAs, by transcription 
DNA templates for L6 BCR-ABL substrate mRNA and for the normal 
ABL substrate mRNA were synthesized chemically [28]. The DNA tem- 
plate for L6 BCR-ABL substrate mRNA consisted of the sequence 
from 63 nt 5’ of the BCR-ABL junction to 58 nt 3’ of the BCR-ABL 
junction. The region of the DNA template for the normal ABL substrate 
mRNA extended from position 192 to position 283 of normal ABL 
cDNA [5-71. Primers were also synthesized for each template, and 
each sense strand contained a 17 promoter. The sequences of the 5’ 
and the 3’ primers for L6 BCR-ABL substrate mRNA were 5’-TAA 
TAC GAC TCA CTA TAG GGA CAA CTC GTG TGT GAA ACT C-3’ 
and 5’.GCG GCT TCA CTC AGA CCC TGA GGC T-3’. The 
sequences of the 5’ and the 3’ primers for the normal ABL substrate 
mRNA were 5’.TAA TAC GAC TCA CTA TAG GGC TGT CCT CGT 
CCT CCA GCT G-3’ and 5’-GCG GCT TCA CTC AGA CCC TGA 
GGC T-3’. Products of polymerase chain reactions (PCRs) were gel- 
purified. T7 transcription M, vitro and gel-electrophoretic purification of 
the ABL, BCR-ABL mRNA substrates were performed as described 
elsewhere 128,681. The lengths of the L6 BCR-ABL and Af3L mRNA 
substrates were 121 and 92 nts, respectively. 
Analysis of cleavage activities and specificities of DNA 
enzymes in vitro 
Assays of activities and specificities of DNA enzymes were performed, 
in 25 mM MgCI, and 50 mM Tris-HCI (pH 8.0) at 37°C under enzyme- 
saturating (single-turnover) condrtions in which all the available sub- 
strate was expected to form a Michaelis-Menten complex, with high 
concentrations of the DNA enzyme and incubation for 10, 40 and 
120 min or 1, 3 and 6 h as indicated in Figures 3 and 4. The substrate 
@CR-ABL 121 -mer substrate or normal ABL 92-mer) was labeled 
with [y-s*P]-ATP by T4 polynucleotide kinase (Takara Shuzo, Kyoto, 
Japan). Each enzyme was incubated at 1 j,tM with 2 nM 5’-32P-labeled 
substrate. Reactions were stopped at intervals by removal of aliquots 
from the reaction mixture and mixing them with an equal volume of a 
solution that contained 100 mM EDTA, 9 M urea. 0.1% xylene cyanol 
and O.lo/, bromophenol blue. The substrate and the products of the 
reaction were separated by electrophoresrs on a 5% polyacrylamidel 
7 M urea denaturing gel and were detected by autoradiography. The 
extent of cleavage was determined by quantitation of radioactivity in the 
bands of substrate and products with a Bio-image Analyzer 
(BASZOOO; Fuji Film, Tokyo). 
Kinetic analysis 
Kinetic analysis of reactions catalyzed by DNA enzymes were per- 
formed with the BCR-ABL 121 -mer substrate. Reaction rates were 
measured, in 25 mM MgCI, and 50 mM Tris-HCI (pH 8.0), under 
enzyme-saturating (single-turnover) conditions at 37°C as described 
above. Cleavage rates were obtained from the slopes of the curves that 
represented the time-course of each reaction at the initial stage, and 
K, and k,,, were calculated from Eadie-Hofstee plots. For determina- 
tions of K, and k,,,, five different concentrations of enzyme (0.01, 0.02, 
0.05, 0.25 and 1 PM), spanning the K,, were used and calculated 
values are summarized in Table 1. Cited values are averages of results 
from duplicate experiments (two sets of Eadie-Hofstee plots). 
Luciferase assay 
To measure luciferase activity, HeLa S3 cells were plated at 2 x 1 O5 
cells/well in a six-well plate 1 day prior to the (co)-transfection and 
incubated at 37°C in a CO, incubator. Plated HeLa S3 cells were 
washed twice with phosphate-buffered saline (PBS) and placed in 
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500 pl of serum-reduced medium (OPTI-MEM I, Gibco BRL) before the 
(co)-transfection, In the assay shown in Figure 6, 3 f.rg of each oligonu- 
cleotide (DNA enzyme, Antisense DNA etc.; final concentrations of 
each oligonucleotides were about 0.3 pM) and 3 pg of target express- 
ing plasmid (pB2A2-luc or pABL-luc) were mixed with 6 pl of Lipofectin 
reagent (Gibco-BRL, Rockville, MD) in 500 pl of OPTI-MEM I medium, 
and incubated for 30 min at room temperature. After the incubation, the 
mixture was added gently to cells in OPTI-MEM I medium. After 2 h, the 
medium was replaced by the growth medium (DMEM) with 10% FCS 
and cells were cultured for another 10 h. 
In the assay with high concentrations of oligonucleotides, the target 
expression plasmid and the oligonucleotide were added separately to 
cultured cells, in contrast to the experiments shown in Figure 6 (in 
which the oligonucleotides and the target-gene-expressing plasmid 
were simultaneously added to cells). The target-expressing plasmid 
(3 pg) was mixed with 6 pl Lipofectin in 500 pl of OPTI-MEM I medium, 
and incubated for 30 min at room temperature. After the incubation, the 
mixture was added gently to cells in 500 pl of OPTI-MEM I medium. 
After 2 h, HeLa S3 cells were washed twice with PBS and placed in 
500~1 of OPTI-MEM I for the second transfection. Ten nanomol of 
each oligonucleotide (final concentrations of each oligonucleotide were 
10uM) was mixed with 6 ul Lipofectin in 500 f.11 of OPTI-MEM I 
medium, and the mixture was added to cells similarly. After incubation 
for 2 h, the medium was replaced by DMEM containing 10% FCS and 
cells were cultured for another 10 h. 
Luciferase activity was measured with a PicaGene kit (Toyo-inki, Tokyo, 
Japan) as described elsewhere [29,56,71]. In order to normalize the 
efficiency of transfection by reference to P-galactosidase activity, 
cells were co-transfected with the pSV$-Galactosidase control vector 
(Promega, Madison, WI) and then the chemrluminescent signal due to 
P-galactosidase was determined using a luminescent /3-galactosidase 
genetic reporter system (Clontech, Palo Alto, CA) as described in the 
user bulletin [7 1 I. 
RNase H assay 
The short RNA substrate S31, which is complementary to the binding 
sites of LDz3, was hybridized either with the DNA enzyme or with the 
antisense DNA prior to the RNase H treatment. Hybridization reac- 
tions were carried out in a reaction buffer (20 mM Tris-HCI pH 7.5. 
20 mM KCI, 10 mM MgCI,, 1 mM DTT) containing 10 pM of either 
the DNA enzyme or the antisense DNA, and 20 kcpm (< 2 nM) 32P- 
labeled S31. The mixtures were heated at 90°C for 3 min and 10 units 
of RNase inhibitor (TOYOBO, Osaka, Japan) was added. Samples 
were then incubated at 37’C for 6 h. Finally, the samples were incu- 
bated at 37°C with 0.001 unit of Escherichia co/i RNase H enzyme 
(Promega, WI) and quenched at specific time points. The substrate 
and the products of the reaction were separated by electrophoresis 
on a 20% polyacrylamidel7 M urea denaturing gel and were detected 
by autoradiography, as described above. The sequence of S31 was 
5’.AUC AAU AAG GAA GAA GCC CUU CAG CGG CCA G-3’. The 
sequence of LID23 was 5’-CTG GCC GCT GAA GGG GGC TAA 
CTA CAA CGA TTC TTC CTT ATT GAT-3’. The sequences of Anti-8 
and Anti-l 5 were 5’CTG GGC GCT GAA GGG-3’ and 5’.CTG AAG 
GG-3’. respectively. 
Cell viability and apoptosis 
BV173 and HQ cells were cultured at 5 x 1 O7 ceils/dish in RPMI 1640 
medium containing 10% FCS at 37°C. Each oligonucleotide (DNA 
enzyme, 30 ug) was mixed with 30 ul Lipofectin in 800 pl of OPTI-MEM 
l medium, and incubated for 30 min at room temperature. After the incu- 
bation, the mixture was added gently to cells which had been placed in 
OPTI-MEM I medium. After 2 h, the medium was replaced by growth 
medium (RPM1 1640) containing 10% FCS and cell viability was deter- 
mined by the trypan blue exclusion test, Apoptosis was monitored as 
described previously [72], and cells were stained with 10 ug/ml Hoechst 
33342 (Nippon Gene Co., Toyama, Japan) for 15 min for studies of 
nuclear morphology. After washing and mounting in 90% glycerol120 mM 
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Tris (pH 8.0)/O. 1% N-propyl gallate, slides were examined under a fluo- 
rescent microscope (Nikon, Tokyo). 
Northern blotting analysis 
To detect cleaved BCR-ABL mRNA in BV173 cells, total RNA from 
BVI 73 cells which were transfected with each DNA enzyme as 
described above was isolated with ISOGENrM (Nippon Gene Co., 
Toyama, Japan). Total RNA (50 pg per lane) was loaded on an agarose 
gel (FMC Inc., Rockland, ME) and, after electrophoresis, bands of RNA 
were transferred to a Hybond-NTM nylon membrane (Amersham Co., 
Buckinghamshire, UK). The membrane was probed with a synthetic 
oligonucleotide (5’~TCA GAT GCT ACT GGC CGC TGA AGG GCT 
T-3’, complementary to the sequence of ABL mRNA) that had been 
labeled with 32P by T4 polynucleotide kinase (Takara Shuzo Co., 
Kyoto). Prehybridization and hybridization were performed as described 
previously [29,563. To detect cleavage by the DNA enzyme during the 
RNA isolation, total RNAs from BVl73 cells (1 x 1 O7 cells) that had not 
been transfected with the DNA enzyme were isolated with 1 ml of ISO- 
GENTM containing 20 pg of MeODz3. Then, the RNAs were detected 
by Northern blotting analysis as described previously [29,56]. 
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